Test of immunotherapy plus pills and chemotherapy for advanced melanoma
Treatments studied
Part of Cancer clinical trials.
This Phase 3 trial tests camrelizumab (an immune-boosting medicine) combined with apatinib (a targeted pill) and temozolomide (chemotherapy) as first treatment for advanced acral melanoma. It may help shrink the cancer and improve outcomes compared with other standard first-line options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and can give written consent.
- Your acral melanoma has come back, can’t be fully removed by surgery, or has spread to other parts of the body (stage III or IV).
- You have not yet had any whole-body (systemic) anti-cancer treatment such as immunotherapy, targeted therapy, chemotherapy, or similar.
- Your scans show measurable cancer areas (measurable disease) and you’re expected to live more than 12 weeks.
- Your general functioning is good enough (ECOG 0 to 1) and your organs are working well enough for treatment.
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests three medicines given before surgery for people with high-risk acral melanoma (a skin cancer type). It aims to shrink or control the cancer earlier and see how well the treatment works and is tolerated.
This trial tests a combination of two immunotherapy drugs with standard chemotherapy (bevacizumab, albumin-bound paclitaxel, and carboplatin) for people with advanced acral or mucosal melanoma. The goal is to see if this combination can shrink tumors or slow the cancer's growth better than current treatments.
This trial tests whether giving two drugs (QL1706 and OH2) before and after surgery can help treat stage III acral melanoma, a type of skin cancer on the palms, soles, or under nails. The goal is to see if this approach reduces the chance of the cancer coming back.
This trial tests two medicines given before surgery to shrink stage III–IV acral melanoma (a melanoma type on the hands/feet) and improve outcomes. If the tumors respond, surgery can happen afterward as planned.
This trial tests a combination of three drugs (Fluzoparib, Camrelizumab, and Temozolomide) for people with advanced melanoma that has spread or cannot be removed by surgery. It is for those who have a specific genetic change (HR or SF3B1 mutation) and have not been treated with a PARP inhibitor before.
This study tests a new oral drug called ST-1898 for people with advanced acral melanoma that has not responded to standard treatments. It aims to see if the drug can shrink or slow the growth of the cancer.
Hear when a new Acral Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.